Associate Professor Sarah Lewington
BSc, MSc, DPhil
Associate Professor of Statistical Epidemiology, Director of Graduate Studies (Taught courses)
- MRC PHRU Programme Leader
- Research Fellow, Green Templeton College
Sarah Lewington is one of the Scientific Directors for the MSc in Global Health Science, with responsibility for the planning, development, delivery and management of all aspects of the fully revised MSc degree course. Sarah graduated in Mathematics and Statistics from Leicester University in 1988 and spent 5 years working as a medical statistician in the pharmaceutical industry before returning to university to study for an MSc in Applied Statistics at Southampton University. She came to Oxford University to co-ordinate the Prospective Studies Collaboration in 1995 and gained her DPhil in Epidemiology in 1999. Sarah’s main research interest is in major risk factors for premature adult mortality, with a particular focus on tobacco, alcohol, blood pressure and obesity, and is the Oxford-based principal investigator for studies conducted in Russia, Cuba and India. She leads a team of epidemiologists, statisticians and statistical programmers that forms the CTSU’s Population Studies Group and is the MRC Progamme Leader Track, Statistical Epidemiology.
Sex-specific relevance of diabetes to occlusive vascular and other mortality: Meta-analysis of individual data from 68 prospective studies with 77,000 deaths among 1 million adults
Lewington S. et al, (2018), The Lancet Diabetes and Endocrinology
Characteristics and correlates of sleep duration, daytime napping, snoring and insomnia symptoms among 0.5 million Chinese men and women.
Chen Y. et al, (2018), Sleep Med, 44, 67 - 75
Cohort Profile: The Korean Cancer Prevention Study-II (KCPS-II) Biobank.
Jee YH. et al, (2018), Int J Epidemiol, 47, 385 - 386f
Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study.
Herrington WG. et al, (2018), Lancet Diabetes Endocrinol
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Aung T. et al, (2018), JAMA Cardiol, 3, 225 - 234